risks

My brother is getting married in two weeks, so last weekend, I attended my future sister-in-law’s bridal shower in London. When it came to managing my relapsing-remitting MS (RRMS) on the trip, I pretty much broke every rule I live by. Surprisingly, taking risks paid off for me, which…

A tragic car crash involving a man with MS is a reminder that we all should be just a little bit more careful than the average driver when we get behind the wheel. The accident happened in early October on a street in Eugene, Oregon. As reported by…

Previously unpublished results of clinical trials of Lemtrada (alemtuzumab) appears to contain key information as to why many multiple sclerosis patients who use it develop other autoimmune diseases. Researchers looked at the immune cell mix after Lemtrada depleted many of those cells. They discovered that certain B-cells repopulate the body earlier…

Scientists at Stanford University School of Medicine have developed a method for stem cell transplants that may do away with the need for prior systematic treatment with chemotherapy or radiotherapy. If successful, stem cell transplants could be an option for patients with multiple sclerosis (MS), an option now limited by the…

Previous studies suggested that multiple sclerosis (MS) and Hodgkin lymphoma might share underlying causes, including exposure to microorganisms in childhood, such as Epstein-Barr virus (EBV) infection. In the study “Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma,” published in the journal Neurology: Neuroimmunology and Neuroinflammation, researchers suggested that…

The National Multiple Sclerosis Society is funding a new survey to understand how people living with multiple sclerosis (MS) weigh risks against benefits when choosing MS therapies. The survey was developed by Dr. Robert Fox, a neurologist, working with colleagues at the Cleveland Clinic and the MS patient…

Dr. Andrew Goodman of the University of Rochester discussed the latest research and perspectives on stem cell strategies for people with multiple sclerosis (MS), saying in a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 that such therapies, while promising, are not yet ready for widespread clinical use. New therapies…